GlassScriptPhysician profile
Aekata Shah
NPI 1972984458
$9,958.83
in general payments reported to CMS, 2019-2025
39 companies · $1,009 in 2025
The $1,009 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,528 · 2020: $1,101 · 2021: $1,524 · 2022: $1,421 · 2023: $1,694 · 2024: $1,681 · 2025: $1,009.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,271 · Education: $113.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,271.00 |
| Education | $113.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,241.96 | 2019-2025 | Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $1,120.65 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Abbvie INC. | $1,047.39 | 2020-2025 | Vraylar, Ubrelvy, Linzess |
| Novo Nordisk INC | $1,029.26 | 2021-2025 | Ozempic, Rybelsus |
| Gilead Sciences, INC. | $1,009.91 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $561.31 | 2023-2025 | |
| Allergan, INC. | $521.47 | 2019-2020 | |
| Astellas Pharma US INC | $421.53 | 2019-2025 | Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $409.85 | 2019-2025 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $407.87 | 2021-2025 | Jardiance, Synjardy |
| Takeda Pharmaceuticals U.S.A., INC. | $340.87 | 2019-2021 | |
| Lilly USA, LLC | $285.91 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| E.R. Squibb & Sons, L.L.C. | $259.37 | 2021-2024 | Camzyos, Eliquis |
| Pfizer INC. | $227.83 | 2020-2025 | |
| Nestle Healthcare Nutrition INC. | $122.84 | 2021 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aekata Shah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.